| Arctic Chiropractic Huffman | |
|
1389 Huffman Park Dr Ste 140, Anchorage, AK 99515-3534 | |
| (907) 222-6122 | |
| Not Available |
| Full Name | Arctic Chiropractic Huffman |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 1389 Huffman Park Dr Ste 140, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316402720 | NPI | - | NPPES |
| Provider Name | Joel A Ingersoll |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1831399575 PECOS PAC ID: 9830310440 Enrollment ID: I20141024000298 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
| Provider Name | Daniel A Buckley |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1497246177 PECOS PAC ID: 9931445046 Enrollment ID: I20190110002049 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
| Provider Name | Brent Wise |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1285921833 PECOS PAC ID: 3870741358 Enrollment ID: I20190606000329 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
| Provider Name | Jessica M Quinn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295336659 PECOS PAC ID: 2062824469 Enrollment ID: I20201208002933 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
| Provider Name | Allison M Guerin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629715743 PECOS PAC ID: 3870970163 Enrollment ID: I20220505002017 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arctic Chiropractic Huffman 1389 Huffman Park Dr Ste 140, Anchorage, AK 99515-3534 Ph: (907) 222-6122 | Arctic Chiropractic Huffman 1389 Huffman Park Dr Ste 140, Anchorage, AK 99515-3534 Ph: (907) 222-6122 |
News Archive
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.
› Verified 9 days ago
Arctic Chiropractic Barrow Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 4000 W Dimond Blvd, Ste #4, Anchorage, AK 99502 Phone: 907-852-3099 Fax: 907-852-3225 | |
Chiro One Wellness Center Of Anchorage South Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 4000 W Dimond Blvd Unit 4, Anchorage, AK 99502 Phone: 907-243-0660 | |
Dr. Jonathan D. Vito, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8840 Old Seward Hwy Ste E, Anchorage, AK 99515 Phone: 907-346-5255 Fax: 907-346-5256 | |
Arctic Rehabilitation And Physical Therapy Anchorage Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 5701 Lake Otis Pkwy, Suite 100, Anchorage, AK 99507 Phone: 907-277-3422 | |
Dr. Kelly Brian Ryan, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 550 E Tudor Rd, Anchorage, AK 99503 Phone: 907-222-2100 Fax: 907-222-2131 | |
Dr. Elliott Shawn Woodmansee, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 750 W Dimond Blvd, Suite 121, Anchorage, AK 99515 Phone: 907-344-0033 Fax: 907-344-6332 | |
Dr. Wesley Moore, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 505 W Northern Lights Blvd, Anchorage, AK 99503 Phone: 907-339-0100 Fax: 907-334-1961 |